(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.89%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.83%.
Reviva Pharmaceuticals Holdings's earnings in 2026 is -$22,756,700.On average, 10 Wall Street analysts forecast RVPH's earnings for 2026 to be -$33,700,670, with the lowest RVPH earnings forecast at -$95,843,830, and the highest RVPH earnings forecast at $0. On average, 7 Wall Street analysts forecast RVPH's earnings for 2027 to be -$34,034,340, with the lowest RVPH earnings forecast at -$55,251,149, and the highest RVPH earnings forecast at -$7,248,693.
In 2028, RVPH is forecast to generate -$8,215,185 in earnings, with the lowest earnings forecast at -$45,102,979 and the highest earnings forecast at $31,411,003.